Maintenance is an active process, not a static one
Scenario A: Metabolic Rescue (High Risk, Suitable for Application) Target population: women with BMI 30 kg/m 2 plus marked IR or metabolic syndrome
Repeatedly injecting in the same location can lead to lipohypertrophy, a condition characterized by lumpy, thickened areas of fatty tissue that can impair medication absorption and lead to unpredictable blood glucose levels
If you find your vision changes, you should stop taking the medication and contact a medical professional as soon as possible
In the Phase REDEFINE 4 trial, CagriSemaa fixed dose combo of 2.4 mg semaglutide and 2.4 mg cagrilintideelicited 23% weight loss over 84 weeks compared to Zepbounds 25.5%
Frequently asked questions about GLP-1 patches Here are a few questions people often ask about GLP-1 supplement patches